XENE
Xenon Pharmaceuticals Inc.
$56.44
+0.79%
2026-05-08
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Key Fundamentals
Forward P/E
-11.95
EPS (TTM)
$-4.36
ROE
-51.8%
Profit Margin
0.0%
Debt/Equity
1.37
Price/Book
7.78
Beta
0.65
Market Cap
$5.47B
Avg Volume (10D)
1.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$63.95
60D Low
$40.86
Avg Volume
1.4M
Latest Close
$56.44
Get breakout alerts for XENE
Sign up for Breakout Scanner to receive daily notifications when XENE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Xenon Pharmaceuticals Inc. (XENE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors XENE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. XENE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.